Friday, June 02, 2023 1:29:01 PM
HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 701,756 shares of the Company’s common stock at a purchase price of $2.1375 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series C preferred investment options. The series C preferred investment options to purchase up to 350,878 shares of common stock have an exercise price of $2.075 per share and are immediately exercisable for a period of five and one-half years following issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about June 6, 2023, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.
Recent MBOT News
- Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™ • GlobeNewswire Inc. • 04/29/2024 12:30:00 PM
- Microbot Medical Shares Status Following Recent Geopolitical Events • GlobeNewswire Inc. • 04/15/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:41:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:41:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:41:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:41:08 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 09:35:10 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:49:35 PM
- Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US • GlobeNewswire Inc. • 02/05/2024 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/30/2024 09:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 12:20:27 PM
- Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters • GlobeNewswire Inc. • 01/30/2024 12:20:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/26/2024 05:15:33 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/22/2024 10:20:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 12:20:26 PM
- Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study • GlobeNewswire Inc. • 01/18/2024 12:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 09:20:41 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 09:16:06 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/02/2024 10:00:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:55:51 PM
- Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 12/29/2023 01:00:00 PM
- Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met • GlobeNewswire Inc. • 12/28/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 01:15:27 PM
- Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic • GlobeNewswire Inc. • 12/14/2023 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 01:00:28 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM